NBIX Form 4 reports multiple insider transactions
BENEVICH ERIC reported multiple insider transaction types in a Form 4 filing for NBIX.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BENEVICH ERIC reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 83,590 shares at a weighted average price of $124.03 per share. Following the reported transactions, holdings were 3,924 shares.
Insider Trade Summary
6,049 shares exercised/converted
Exercise
13 txns
Insider
BENEVICH ERIC
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,961 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 2,083 | $0.00 | $0.00 |
| Grant/Award | Stock Option | 36,287 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 6,365 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,961 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,058 | $124.12 | $131K |
| Exercise | Common Stock | 2,083 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,124 | $124.12 | $140K |
| Grant/Award | Common Stock | 16,613 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 8,963 | $124.12 | $1.11M |
| Exercise | Restricted Stock Unit | 2,005 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,005 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,082 | $123.10 | $133K |
Holdings After Transaction:
Restricted Stock Unit — 18,389 contracts (Direct);
Stock Option — 36,287 contracts (Direct);
Common Stock — 63,190 shares (Direct)
Footnotes (8)
- F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- F2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- F3. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F4. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,005 shares on February 12, 2026, and will vest as to 2,005 shares on February 12, 2027, 2,005 shares on February 12, 2028, and 2,005 shares on February 12, 2029, subject to the terms and conditions of the award.
- F5. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award.
- F6. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.
- F7. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F8. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did NBIX’s Chief Commercial Officer report?
Eric Benevich reported equity compensation activity including RSU and PRSU vesting, new RSU and stock option grants, and share withholding for taxes. These transactions increased his direct common stock holdings while settling tax obligations without open-market share sales.
What new stock options were granted to NBIX’s Chief Commercial Officer?
He received a stock option covering 36,287 Neurocrine Biosciences common shares at an exercise price of $124.12 per share. One forty-eighth of the option vests monthly starting March 13, 2026, with the remainder vesting in equal monthly installments thereafter.
What future vesting schedules are disclosed for NBIX RSU and option awards?
Time-based RSUs vest annually through February 2029 for a 2025 grant and through February 2028 for a 2024 grant. Another RSU grant vests through February 2027. The new option vests monthly starting March 13, 2026, while additional RSUs vest annually from 2027 to 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates